At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
Bermekimab Monoclonal Antibody +1 moredrug
Likely dose
Bermekimab Monoclonal Antibody 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Bermekimab Monoclonal Antibody and Placebo for Atopic Dermatitis and Eczema. Completed, enrolled 87 participants across 17 sites.
Detailed Summary
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Eczema
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartOct 2019
Primary CompletionJun 2020
Study CompletionNov 2020
TodayJul 2026
First PostedJul 16, 2019
Enrollment StartOct 16, 2019
Primary CompletionJun 30, 2020
Study CompletionNov 19, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.0 years ago
Interventions
Bermekimab Monoclonal Antibodydrug
Bermekimab 400 mg or 800 mg will be administered subcutaneously.
Placebodrug
Placebo will be administered subcutaneously.